Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C40H65O13.K |
Molecular Weight | 793.0346 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 17 / 17 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].[H][C@@]1(C[C@H](C)[C@@]([H])(O1)[C@]2(C)CC[C@@]([H])(O2)[C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@]([H])(O4)[C@@H](C)[C@@H](OC(=O)CC)[C@H](C)C([O-])=O)O3)[C@@]5([H])O[C@@](O)(COC(=O)CC)[C@H](C)C[C@@H]5C
InChI
InChIKey=OXNOQXLCECXEBU-QGMAIPBJSA-M
InChI=1S/C40H66O13.K/c1-11-30(42)47-20-40(46)23(5)17-21(3)32(52-40)28-18-22(4)35(48-28)38(10)14-13-29(50-38)37(9)15-16-39(53-37)19-27(41)24(6)34(51-39)25(7)33(26(8)36(44)45)49-31(43)12-2;/h21-29,32-35,41,46H,11-20H2,1-10H3,(H,44,45);/q;+1/p-1/t21-,22-,23+,24+,25-,26-,27-,28+,29+,32-,33+,34-,35+,37-,38-,39+,40-;/m0./s1
Molecular Formula | K |
Molecular Weight | 39.0983 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C40H65O13 |
Molecular Weight | 753.9363 |
Charge | -1 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 17 / 17 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Laidlomycin is a polycyclic polyether antibiotic which possesses an inhibitory activity against various mycoplasma species}, and is effective in controlling coccidiosis in chickens. It is also known as selectively inhibiting the
migration of hemagglutinin glycoprotein from Golgi apparatus to the cell surface in measles virus). Laidlomycin inhibited growth of some Gram-positive bacteria only at high concentrations such as 50-100 ug/ml,
but was not active against Gram-negative bacteria,
yeast and fungi even at concentration of 1,000 ug/ml. In broth dilution, laidlomycin was active against several illycoplasmas and most active against the sterol-nonrequiring mycoplasma, Acholeplasma laidlawii. Under the brand name Cattlyst Laidlomycin is indicated for improved feed efficiency and increased rate of weight gain in cattle fed in confinement for slaughter.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL378 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11099233 |
|||
Target ID: CHEMBL612313 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9814916 |
|||
Target ID: GO:0006811 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Cattlyst Approved UseFor improved feed efficiency and increased rate of weight gain in cattle fed in confinement for slaughter Launch Date1994 |
PubMed
Title | Date | PubMed |
---|---|---|
Ionophores have limited effects on jejunal glucose absorption and energy metabolism in mice. | 2003 Aug |
|
Inhibition of resistance plasmid transfer in Escherichia coli by ionophores, chlortetracycline, bacitracin, and ionophore/antimicrobial combinations. | 2004 Apr-Jun |
|
Production and biological activity of laidlomycin, anti-MRSA/VRE antibiotic from Streptomyces sp. CS684. | 2007 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.betterchem.com/vet/laidlomycin.htm
Laidlomycin propionate promix, 50 g of laidlomycin propionate potassium per pound. Laidlomycin propionate premix should be admixed into feed and fed at a dietary concentration of 5 to 10 g of laidlomycin propionate/ton of feed (90% dry matter basis) to provide not less than 30 nor more than 150 mg/animal/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12926789
Laidlomycin propionate (16.2 mM) decreased (P < 0.02) glucose absorption, as estimated by H3-3-O-methyl glucose uptake compared with all other treatments of murine jejunal rings, whereas laidlomycin propionate (1.62 mM) increased (P = 0.032) jejunal DM content compared with 16.2 mM laidlomycin propionate.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:39:19 GMT 2023
by
admin
on
Fri Dec 15 16:39:19 GMT 2023
|
Record UNII |
05TAA9I0Z8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C258
Created by
admin on Fri Dec 15 16:39:19 GMT 2023 , Edited by admin on Fri Dec 15 16:39:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C79534
Created by
admin on Fri Dec 15 16:39:19 GMT 2023 , Edited by admin on Fri Dec 15 16:39:19 GMT 2023
|
PRIMARY | |||
|
AA-103
Created by
admin on Fri Dec 15 16:39:19 GMT 2023 , Edited by admin on Fri Dec 15 16:39:19 GMT 2023
|
PRIMARY | |||
|
m6667
Created by
admin on Fri Dec 15 16:39:19 GMT 2023 , Edited by admin on Fri Dec 15 16:39:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
23674236
Created by
admin on Fri Dec 15 16:39:19 GMT 2023 , Edited by admin on Fri Dec 15 16:39:19 GMT 2023
|
PRIMARY | |||
|
DTXSID001005083
Created by
admin on Fri Dec 15 16:39:19 GMT 2023 , Edited by admin on Fri Dec 15 16:39:19 GMT 2023
|
PRIMARY | |||
|
05TAA9I0Z8
Created by
admin on Fri Dec 15 16:39:19 GMT 2023 , Edited by admin on Fri Dec 15 16:39:19 GMT 2023
|
PRIMARY | |||
|
1306103
Created by
admin on Fri Dec 15 16:39:19 GMT 2023 , Edited by admin on Fri Dec 15 16:39:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL2110869
Created by
admin on Fri Dec 15 16:39:19 GMT 2023 , Edited by admin on Fri Dec 15 16:39:19 GMT 2023
|
PRIMARY | |||
|
05TAA9I0Z8
Created by
admin on Fri Dec 15 16:39:19 GMT 2023 , Edited by admin on Fri Dec 15 16:39:19 GMT 2023
|
PRIMARY | |||
|
84799-02-0
Created by
admin on Fri Dec 15 16:39:19 GMT 2023 , Edited by admin on Fri Dec 15 16:39:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |